{"organizations": [], "uuid": "9fb44f80d8cad4ad828d465af42d7bd16049a45d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/16/globe-newswire-kane-biotech-schedules-fourth-quarter-and-full-year-2017-earnings-conference-call-and-business-update.html", "country": "US", "domain_rank": 767, "title": "Kane Biotech Schedules Fourth Quarter and Full Year 2017 Earnings Conference Call and Business Update", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-16T17:53:00.000+02:00", "replies_count": 0, "uuid": "9fb44f80d8cad4ad828d465af42d7bd16049a45d"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/16/globe-newswire-kane-biotech-schedules-fourth-quarter-and-full-year-2017-earnings-conference-call-and-business-update.html", "ord_in_thread": 0, "title": "Kane Biotech Schedules Fourth Quarter and Full Year 2017 Earnings Conference Call and Business Update", "locations": [], "entities": {"persons": [{"name": "mark ahrens-townsend", "sentiment": "none"}, {"name": "ray dupuis", "sentiment": "none"}, {"name": "kane", "sentiment": "none"}], "locations": [{"name": "manitoba", "sentiment": "none"}, {"name": "winnipeg", "sentiment": "none"}, {"name": "canada", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "kane biotech inc.", "sentiment": "negative"}, {"name": "kane biotech schedules fourth quarter", "sentiment": "negative"}, {"name": "e.t. u.s. & canada dial-in", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "WINNIPEG, Manitoba, March 16, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce that it will host a conference call on Thursday, March 22, 2018 at 4:30pm E.T. to discuss its financial results for the fourth quarter and full year 2017, in conjunction with the filing of its annual Year End Financial Statements for the fourth quarter and full year ended December 31, 2017.\nMark Ahrens-Townsend, President and Chief Executive Officer, and Ray Dupuis, Chief Financial Officer of Kane, will host the call and provide an update on recent developments and clinical progress. Management will be answering questions live immediately following the earnings announcement part of the call.\nTo participate in the call, please dial +1 877-268-9044 (toll-free) in the U.S. and Canada. The conference ID number is 2680589.\nEvent: FY+ 2017 Earnings and Business Update Conference Call Date: Thursday, March 22, 2018 Time: 4:30pm E.T. U.S. & Canada Dial-in: 877-268-9044 (toll free) Conference ID: 2680589 Webcast Link: https://edge.media-server.com/m6/p/pvvmdwpp A live audio webcast of the conference call will also be available on the investor relations page of Kane’s corporate website at www.kanebiotech.com In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Kane’s website.\nAbout Kane Biotech\nKane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.\nThe Corporation has a portfolio of biotechnologies, intellectual property (75 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol \"KNE\" and on the OTCQB Venture Market under the symbol “KNBIF”.\nFor more information, please visit www.kanebiotech.com or contact:\nMark Ahrens-Townsend\nPresident & CEO, Kane Biotech Inc.\nir@kanebiotech.com\n+1 (204) 477-7592\nTirth Patel\nEdison Advisors\nInvestor Relations\ntpatel@edisongroup.com\n+1 (646) 653-7035\nNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.\nSource:Kane Biotech Inc.", "external_links": ["https://urldefense.proofpoint.com/v2/url?u=https-3A__edge.media-2Dserver.com_m6_p_pvvmdwpp&d=DwMGaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=4jbTPg1NL6hVjSZApd5UlD0qeplZlqkPrPsxigDEDws&m=SPoCK-Oh81KcNuRG6OYCKCPcy0bYyQ0LXciSv7NIWyQ&s=19zLTXVkaz6_xtZUwThMIn5Qw170c7eUzACnuiqWEys&e=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/49de765b-f1e6-471f-9a91-49dc3dd4eb6b", "https://edge.media-server.com/m6/p/pvvmdwpp"], "published": "2018-03-16T17:53:00.000+02:00", "crawled": "2018-03-16T20:47:30.009+02:00", "highlightTitle": ""}